Navellier & Associates Inc. Buys New Shares in Indivior PLC $INDV

Navellier & Associates Inc. bought a new position in shares of Indivior PLC (NASDAQ:INDV) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 173,860 shares of the company’s stock, valued at approximately $7,133,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Quarry LP bought a new position in shares of Indivior in the third quarter valued at $26,000. Caitong International Asset Management Co. Ltd boosted its stake in shares of Indivior by 72.7% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,093 shares of the company’s stock worth $39,000 after acquiring an additional 460 shares in the last quarter. Rockefeller Capital Management L.P. boosted its stake in shares of Indivior by 512.4% during the 4th quarter. Rockefeller Capital Management L.P. now owns 1,286 shares of the company’s stock worth $46,000 after acquiring an additional 1,076 shares in the last quarter. GAMMA Investing LLC acquired a new position in shares of Indivior in the 2nd quarter worth $66,000. Finally, Raymond James Financial Inc. acquired a new position in shares of Indivior in the 2nd quarter worth $26,000. Institutional investors and hedge funds own 60.33% of the company’s stock.

Insider Buying and Selling

In other news, CFO Ryan Preblick sold 36,000 shares of the company’s stock in a transaction dated Monday, June 8th. The stock was sold at an average price of $37.70, for a total transaction of $1,357,200.00. Following the completion of the sale, the chief financial officer owned 284,751 shares in the company, valued at approximately $10,735,112.70. This represents a 11.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Woodrow D. Anderson acquired 1,500 shares of the stock in a transaction dated Thursday, August 27th. The shares were bought at an average cost of $35.69 per share, for a total transaction of $53,535.00. Following the acquisition, the chief accounting officer owned 27,638 shares in the company, valued at $986,400.22. The trade was a 5.74% increase in their position. The disclosure for this purchase is available in the SEC filing. 0.74% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Barclays reduced their target price on Indivior from $46.00 to $43.00 and set an “overweight” rating for the company in a report on Wednesday, August 5th. Craig Hallum restated a “buy” rating and set a $53.00 price objective on shares of Indivior in a report on Tuesday, August 4th. Zacks Research downgraded Indivior from a “strong-buy” rating to a “hold” rating in a report on Monday, June 29th. Finally, Weiss Ratings cut shares of Indivior from a “buy (b-)” rating to a “hold (c+)” rating in a report on Friday, August 21st. Five research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $45.17.

Indivior Stock Down 1.2%

Shares of NASDAQ:INDV opened at $34.87 on Friday. The firm has a fifty day moving average of $39.33 and a two-hundred day moving average of $36.00. Indivior PLC has a 12-month low of $22.22 and a 12-month high of $42.81. The firm has a market capitalization of $4.12 billion, a P/E ratio of 12.50 and a beta of 0.86.

Indivior (NASDAQ:INDV) last issued its earnings results on Tuesday, June 30th. The company reported $5.75 earnings per share for the quarter. The company had revenue of $343.00 million for the quarter. Indivior had a negative return on equity of 283.11% and a net margin of 26.65%. Equities research analysts expect that Indivior PLC will post 3.66 earnings per share for the current fiscal year.

Indivior Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.